BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
14 January 2022 - 12:31AM
Dow Jones News
By Colin Kellaher
BridgeBio Pharma Inc. on Thursday said it plans to evaluate its
BBP-398 small-molecular inhibitor in combination with Amgen Inc.'s
cancer drug Lumakras in patients with advanced solid tumors with
the KRAS G12C mutation.
BridgeBio, a Palo Alto, Calif., biopharmaceutical company, said
it will sponsor a Phase 1/2 study designed to evaluate the safety,
tolerability and preliminary efficacy of the combination, while
Amgen will provide a supply of Lumakras.
KRAS mutations occur in roughly 17% of malignant solid tumors.
The U.S. Food and Drug Administration last year approved Lumakras
as the first targeted treatment for patients with KRAS G12C-mutated
locally advanced or metastatic nonsmall-cell lung cancer.
BridgeBio's BBP-398 is an inhibitor of SHP2, an oncoprotein
overexpressed in a variety of cancer cell types inhibitor. The
company is currently advancing a Phase 1 study of BBP-398 in
patients with solid tumors driven by mutations in the MAPK
signaling pathway, including RAS and receptor tyrosine kinase
genes.
BridgeBio last year agreed to collaborate with Bristol Myers
Squibb Co. to evaluate the combination of BBP-398 with Bristol's
blockbuster cancer drug Opdivo in patients with advanced solid
tumors with KRAS mutations.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 13, 2022 08:16 ET (13:16 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024